End stage renal disease and prophylactic intracavitary interferon.
Pascual
J
J
Department of Nephrology, Hospital Ramón y Cajal, Madrid, Spain.
Quereda
C
C
Burgos
F J
FJ
Liaño
F
F
Mampaso
F
F
Frutos
B
B
Ortuño
J
J
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002295:Carcinoma, Transitional Cell / Q000517:prevention & control*; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects*; D007676:Kidney Failure, Chronic / Q000209:etiology*; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D001749:Urinary Bladder Neoplasms / Q000517:prevention & control*
D000970:Antineoplastic Agents; D016898:Interferon-alpha